Biomarin Pharmaceutical (BMRN) revenue breakdown
By product, VOXZOGO is the largest at 29% of fiscal 2025 revenue, growing 255% a year over 4 years.
By region, United States is the largest at 49% of fiscal 2020 revenue; Rest of world grew fastest, 17% a year over 4 years.
Revenue by product
Fiscal years, as Biomarin Pharmaceutical reports them in its 10-K filings; fiscal 2025 total $3.2B.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VOXZOGO | — | — | — | — | — | $6M | $169M | $470M | $735M | $927M | 29% |
| VIMIZIM | — | — | — | — | — | $623M | $664M | $701M | $740M | $792M | 25% |
| NAGLAZYME | — | — | — | — | — | $380M | $444M | $420M | $480M | $485M | 15% |
| PALYNZIQ | — | — | — | — | — | $237M | $255M | $304M | $355M | $433M | 13% |
| ALDURAZYME | — | — | — | — | — | $123M | $128M | $131M | $184M | $209M | 6% |
| BRINEURA | — | — | — | — | — | $128M | $154M | $162M | $169M | $186M | 6% |
| KUVAN | — | — | — | — | — | $286M | $228M | $181M | $121M | $100M | 3% |
| Royalty and other revenues | $6M | $43M | $21M | $43M | $55M | $63M | $54M | $47M | $44M | $53M | 2% |
| ROCTAVIAN | — | — | — | — | — | — | — | $3M | $26M | $36M | 1% |
| Product | $1.1B | $1.3B | $1.5B | $1.7B | $1.8B | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Biomarin Pharmaceutical reports them in its 10-K filings; fiscal 2020 total $1.9B.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | Share |
|---|---|---|---|---|---|---|
| United States | $508M | $588M | $697M | $778M | $912M | 49% |
| Europe | $341M | $399M | $436M | $509M | $518M | 28% |
| Rest of world | $121M | $145M | $173M | $198M | $224M | 12% |
| Latin America | $147M | $182M | $185M | $219M | $206M | 11% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BMRN.
Open BMRN in InvestinglyQuestions
Where does Biomarin Pharmaceutical make its money?
In fiscal 2025, by product: VOXZOGO $927M, VIMIZIM $792M, NAGLAZYME $485M, PALYNZIQ $433M, ALDURAZYME $209M.
From Biomarin Pharmaceutical's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.